雙鷺藥業(002038.SZ):獲得國家藥監局核發的替莫唑胺膠囊(100mg)藥品註冊證書
格隆匯 8 月 31日丨雙鷺藥業(002038.SZ)公告,公司於近日收到國家藥品監督管理局(以下簡稱“國家藥監局”)核准簽發的替莫唑胺膠囊(100mg)“藥品註冊證書”。
藥品名稱:替莫唑胺膠囊
劑型:膠囊劑
規格:100mg
註冊分類:化學藥品4類
藥品生產企業:北京雙鷺藥業股份有限公司
藥品批准文號:國藥準字H20203450
審批結論:根據《中華人民共和國藥品管理法》及有關規定,經審查,本品符合藥品註冊的有關要求,批准註冊,發給藥品註冊證書。
公司本次替莫唑胺膠囊100mg獲批上市將更方便病人搭配20mg規格服用,將提高該產品的市場競爭力和市場佔有率,已成為公司的主力盈利品種,對公司未來的經營業績產生積極的影響。該產品未來生產及銷售可能受到國家政策、市場環境變化等一些不確定性因素的影響。敬請廣大投資者謹慎決策,注意防範投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.